Click here to bypass content and jump to navigation

 

About BEPREVE

Powerful First-Line Therapy for Itching Associated With Allergic Conjunctivitis1,2

Fast and enduring relief of ocular itching3

BEPREVE quickly and effectively reduces ocular itching associated with allergic conjunctivitis. In clinical trials, 95% and 90% of all BEPREVE-treated eyes had a clinically significant reduction (≥1 unit) of ocular itch at onset and 8 hours post dose, respectively (P≤0.05)3

Chart: Fast Relief of Ocular Itch Chart: Long-Last Relieft of Ocular Itch

Even effective for patients with severe ocular itch2

Within 3 minutes of instillation of BEPREVE, more than two-thirds of eyes with severe ocular itching experienced complete relief, compared with only 3% of eyes taking placebo.2

Click here to view the ocular itch grading scale for the Conjunctival Allergen Challenge (CAC).4

Chart: Severe Patients: Quick and Complete Clearance of Itch With Bepreve<sup>2</sup>

As comfortable in the eye as placebo5

Results from a 6-week safety trial of
1534 eyes demonstrated that BEPREVE was as comfortable as placebo upon instillation and at 5 minutes post instillation. As noted in this chart, both BEPREVE and placebo groups reported treatment as "comfortable" on a scale ranging from "comfortable" to "intolerable."5 BEPREVE is a histamine H1-receptor antagonist indicated for the treatment of itching associated with allergic conjunctivitis.1

Chart: Quick Relief With Comfort Equal to Placebo<sup>6</sup>

A heritage of safety

  • Bepotastine besilate has been used in Japan for 10 years, with more than 1 billion systemic doses6
  • The safety of BEPREVE was evaluated in a clinical study of 861 patients over a period of 6 weeks1
  • There are no contraindications to use of BEPREVE1
  • BEPREVE can be used in patients as young as 2 years of age1
  • BEPREVE was found to be safe and well tolerated in clinical trials7

Back to Top

References: 1. BEPREVE [package insert]. Irvine, CA: ISTA Pharmaceuticals, Inc; 2010. 2. Clark JC, Williams JI, Gow JA, et al. Bepotastine besilate ophthalmic solution 1.5% rapidly eliminates ocular itching in more severely allergic subjects in the conjunctival allergen challenge model of allergic conjunctivitis. Poster presented at: Eastern Allergy Conference; May 6-9, 2010; Palm Beach, FL. 3. Williams JI, Schooley GL, Gow JA, McNamara TR. Bepreve™ 1.5% provides clinically meaningful reduction in allergen-induced ocular itching for subjects in an analysis of two phase 3 conjunctival allergen challenge (CAC) clinical trials [AAAAI abstract 151]. J Allergy Clin Immunol. 2010;125(2)(suppl 1):AB38. 4. Abelson MB, Spitalny L. Combined analysis of two studies using the conjunctival allergen challenge model to evaluate olopatadine hydrochloride, a new ophthalmic antiallergic agent with dual activity. Am J Ophthalmol. 1998;125(6):797-804. 5. Data on file. ISTA Pharmaceuticals, Inc. 6. Data on file. ISTA Pharmaceuticals, Inc. 7. Data on file. ISTA Pharmaceuticals, Inc.

IMPORTANT SAFETY INFORMATION: BEPREVE is for topical ophthalmic use only. To minimize risk of contamination, do not touch the dropper tip to any surface. Keep the bottle closed when not in use. BEPREVE should not be used to treat contact lens–related irritation. Remove contact lenses prior to instillation of BEPREVE. The most common adverse reaction occurring in approximately 25% of patients was a mild taste following instillation. Other adverse reactions occurring in 2%-5% of patients were eye irritation, headache, and nasopharyngitis.

Back to Top